Startseite/Aktien/CANF

CANF

USD

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

$1.080-0.030 (-2.703%)

Echtzeitkurs

Healthcare

Biotechnologie

Israel

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen

Unternehmensfundamentaldaten

Handelsstatistiken

Marktkennzahlen

Eröffnung

$1.110

Hoch

$1.110

Tief

$1.080

Volumen

0.07M

Unternehmensfundamentaldaten

Marktkapitalisierung

15.3M

Branche

Biotechnologie

Land

Israel

Handelsstatistiken

Durchschnittliches Volumen

0.28M

Börse

ASE

Währung

USD

52-Wochen-Spanne

Tief $0.98Aktuell $1.080Hoch $4.69

Ähnliche Nachrichten

5. Mai 2025 · 12:00

GlobeNewswire

Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis

Ramat Gan, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory

Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis

17. Apr. 2025 · 12:55

GlobeNewswire

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

15. Apr. 2025 · 11:08

Analyst Upgrades

D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma with a Buy and maintains $10 price target.

D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target

14. Apr. 2025 · 18:28

GlobeNewswire

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

14. Apr. 2025 · 12:30

GlobeNewswire

Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships

Ramat Gan, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory